Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?

Author： Chiolero Arnaud   Burnier Michel   Maillard Marc P  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.1, Iss.1, 2002-05, pp. : 45-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Mechanisms of COX-2 Selective Inhibitors Affecting Cardiovascular Risk

By Smith Howard S.  

Journal of Cancer Pain & Symptom Palliation, Vol. 2, Iss. 3, 2008-01 ,pp. : 5-18

Haworth Press

Access to resources Recommend Favorite

Temporal Relationship between Use of NSAIDs, Including Selective COX-2 Inhibitors, and Cardiovascular Risk

By Motsko Stephen P.  

Drug Safety, Vol. 29, Iss. 7, 2006-01 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite

COX-2 selective inhibitors: analysis of the renal effects

By Perazella Mark A  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 53-64

Informa Healthcare

Access to resources Recommend Favorite

Gastrointestinal Safety of Selective COX-2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 8, Iss. 12, 2002-06 ,pp. : 1077-1089

Bentham Science Publishers

Access to resources Recommend Favorite

Selective COX-2 inhibitors: is the water becoming muddy?

By Wallace J.L.  

Trends in Pharmacological Sciences, Vol. 20, Iss. 1, 1999-01 ,pp. : 4-6

Elsevier

Access to resources Recommend Favorite